EGFR and colorectal carcinoma: Since a previous study found that patients with mutations in FBXW7 may be less likely to respond to anti-EGFR therapy than those without mutations in FBXW7 [12], FBXW7 assessment may be useful to include in molecular testing of patients with left‐sided CRC who would receive targeted therapy.